Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression
Katharina Bonitz(Austrian Academy of Sciences), Philipp Schwabl(Austrian Academy of Sciences), Vlad Țâru(Iuliu Hațieganu University of Medicine and Pharmacy), Hubert Scharnagl(Medical University of Graz), Katharina Regnat(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Katharina Bareiner(Medical University of Vienna), Henriette Horstmeier(Medical University of Vienna), Kerstin Zinober(Medical University of Vienna), Georg KRAMER(Medical University of Vienna), Eric Simon(Boehringer Ingelheim (Germany)), Benedikt Simbrunner(Austrian Academy of Sciences), Katja Sommer(Austrian Academy of Sciences), Stefan Kauscke(Boehringer Ingelheim (Germany)), Oleksander Petrenko(Austrian Academy of Sciences), Michael Trauner(Medical University of Vienna), Philipp Königshofer(Medical University of Vienna), Peng Yan Sun(Boehringer Ingelheim (Germany)), Thomas Sorz(Medical University of Vienna)
Cited by 0
Related Papers
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
|Journal of Hepatology|2020|202
Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis
|Clinical Gastroenterology and Hepatology|2022|130
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis
|Nature Protocols|2015|119